Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 27 of the 34 sources its claims cite were checked for support.

In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans

Open access
Mahmoud, Dina Ezzat, Faraag, Ahmed Hassan Ibrahim, Abu El-Wafa, Wael Mohamed · 2021 · World Journal of Microbiology and Biotechnology

Abstract

The resistance of Candida albicans to azole drugs represents a great global challenge. This study investigates the potential fungicidal effects of atorvastatin (ATO) combinations with fluconazole (FLU), itraconazole (ITR), ketoconazole (KET) and voriconazole (VOR) against thirty-four multidrug-resistant (MDR) C. albicans using checkerboard and time-kill methods. Results showed that 94.12% of these isolates were MDR to ≥ two azole drugs, whereas 5.88% of them were susceptible to azole drugs. The tested isolates exhibited high resistance rates to FLU (58.82%), ITR (52.94%), VOR (47.06%) and KET (35.29%), whereas only three representative (8.82%) isolates were resistant to all tested azoles. Remarkably, the inhibition zones of these isolates were increased at least twofold with the presence of ATO, which interacted in a synergistic (FIC index ≤ 0.5) manner with tested azoles. In silico docking study of ATO and the four azole drugs were performed against the Lanosterol 14-alpha demethylase enzyme (ERG11) of C. albicans. Results showed that the mechanism of action of ATO against C. albicans is similar to that of azole compounds, with a docking score (−4.901) lower than azole drugs (≥5.0) due to the formation a single H-bond with Asp 225 and a pi–pi interaction with Thr 229. Importantly, ATO combinations with ITR, VOR and KET achieved fungicidal effects (≥ 3 Log10 cfu/ml reduction) against the representative isolates, whereas a fungistatic effect (≤ 3 Log10 cfu/ml reduction) was observed with FLU combination. Thus, the combination of ATO with azole drugs could be promising options for treating C. albicans infection.

Overview

CoChat Summary

TL;DR

Atorvastatin (ATO) showed antifungal activity against multidrug-resistant *Candida albicans* and synergized with fluconazole, itraconazole, ketoconazole, and voriconazole in vitro. ATO/azole combinations reduced azole MICs below susceptible breakpoints and produced fungicidal effects with ITR, VOR, and KET, while ATO/FLU was fungistatic.

Key findings

  • Among 34 *C. albicans* isolates, 94.12% (32/34) were multidrug resistant to ≥ two azole drugs, 5.88% (2/34) were susceptible to all tested drugs, and 8.82% (3/34) were resistant to all tested azoles. Azole resistance rates were FLU 58.82%, ITR 52.94%, VOR 47.06%, and KET 35.29%.
  • ATO increased azole inhibition zones at least twofold. Checkerboard testing showed all ATO/azole combinations were synergistic (FIC index ≤ 0.5), with four-fold MIC reductions; MICs decreased from 16–32 to 4.0 mg/l for ATO, 8.0–16 to 1.0–4.0 mg/l for FLU, 1.6–3.2 to 0.2–0.4 mg/l for ITR, 2.0–4.0 to 0.25–0.5 mg/l for VOR, and 1.6–12.8 to 0.4–1.6 mg/l for KET.
  • In time-kill assays, ATO alone at MIC levels produced ≥3 Log10 cfu/ml reductions against representative isolates. ATO (4 mg/l) combined with ITR, VOR, or KET produced synergistic fungicidal effects after 24 h (3.0–3.7 Log10 cfu/ml reduction), whereas ATO/FLU produced a 2.34–2.7 Log10 cfu/ml reduction, reported as fungistatic.
  • Docking against *C. albicans* ERG11 gave ATO a score of −4.901, with a single H-bond to Asp 225 and a pi-pi interaction with His 310 in the Results; ATO’s HMG-CoA reductase binding score was −5.472 with two H-bonds to Gly (C) 715 and Ser (C) 720.

Methods

  • Thirty-four *C. albicans* clinical isolates from Kasr El-Ainy Hospital, Cairo, Egypt (2019–2020), from urine, sputum, pus, wound, and blood, were purified on Chromagar Candida and stored.
  • Susceptibility was tested by CLSI broth microdilution MIC for amphotericin B, FLU, ITR, KET, and VOR; ATO MIC was determined against representative isolates. Disc diffusion was performed on Mueller-Hinton agar with glucose and methylene blue (MHG) containing 0, 0.5, or 1.0 mg/l ATO.
  • Synergy was assessed by checkerboard FIC index (synergism ≤ 0.5; indifference >0.5 to <4; antagonism >4) and time-kill assays in Sabouraud dextrose broth at 0 and 24 h. In silico docking used ERG11 (PDB: 5V5Z) and a homology model of HMG-CoA reductase (PDB: 3cd0) with Schrodinger Maestro/Glide.

Limitations

  • Stated: the number of MDR *C. albicans* isolates was relatively low, and no reference azole-resistant *C. albicans* strains were used; the authors attribute this to COVID-19 quarantine conditions and unavailability of imported reference strains. They also state that further work is needed to confirm results and assess in vivo benefit.
  • Evident from the text: the synergy and time-kill studies used only three representative isolates; the study is entirely in vitro; docking results are computational and not experimentally validated. The text also contains minor discrepancies, e.g., the abstract reports a pi-pi interaction with Thr 229 while the Results/Table report His 310, and the time-kill text reports a 4.13 Log10 reduction for CA3 while the table shows 3.14.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11274-021-03158-4

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

12 Valid · 1 Not valid · 3 Not checked · 50 Own results and interpretations

33 more claims

Create a free account to see all 66 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 18
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 9 · the rest aren’t loaded

4 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 64 references

Cited by

See all 26

Metadata

Authors
Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M.
Affiliations
  • National Organization for Drug Control and Research (EG)
  • Helwan University (EG)
Venue
World Journal of Microbiology and Biotechnology
Published
2021-10-11
Volume
37
Issue
11
Pages
191-191
ISSN
  • 0959-3993 (ISSN-L)
  • 1573-0972
OpenAlex
W3197499973
Cited by
26
References
64
Citations by year
2026: 1 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 5
FWCI
1.42
Type
journal article
Language
en
Open access
Licence
Locations
  • World Journal of Microbiology and Biotechnology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Essential Oils and Antimicrobial Activity
Keywords
atorvastatin, Candida albicans, multidrug resistance, azole antifungals, fluconazole, itraconazole, ketoconazole, voriconazole, drug synergy, fungicidal activity, fungistatic activity, ERG11, lanosterol 14α-demethylase, molecular docking, combination antifungal therapy
MeSH terms
Atorvastatin, Animals, Antifungal Agents, Azoles, Candida albicans, Candidiasis, Fungicides, Industrial, Humans, Ketoconazole, Kinetics, Microbial Sensitivity Tests, Fluconazole, Itraconazole, Drug Resistance, Multiple, Fungal, Molecular Docking Simulation, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans. https://app.cochat.ai/papers/10.1007/s11274-021-03158-4
The paper
Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M. (2021). In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans. World Journal of Microbiology and Biotechnology. https://doi.org/10.1007/s11274-021-03158-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.